Embryonal Carcinoma Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types
Conditions: Sarcoma; Ovarian Neoplasm; Central Nervous System Neoplasm; Thyroid Neoplasm; Carcinoma, Neuroendocrine; Neoplasms, Germ Cell and Embryonal Intervention: Drug: Pembrolizumab Sponsors: UNICANCER; National Cancer Institute, France; Ligue contre le cancer, France; Merck Sharp & Dohme Corp. Not yet recruiting - verified January 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 2, 2017 Category: Research Source Type: clinical trials
